MK-677 (Ibutamoren) Pediatric (<12) Caregiver Administration Guidance

What Is MK-677 and Why Might a Child Under 12 Be Prescribed It?

MK-677 is a non-peptide, orally active agonist of the ghrelin receptor (GHSR-1a) that triggers the pituitary to release growth hormone in a pulsatile pattern closely resembling physiological secretion. Because it works at the receptor level rather than replacing GH directly, it preserves the natural feedback loop through somatostatin, which is one reason researchers have studied it in pediatric growth disorders.

Children under 12 may receive ibutamoren in the following clinical contexts, always through a specialist and never as an over-the-counter supplement:

• Diagnosed growth hormone deficiency (GHD) where injectable GH is contraindicated or refused
• Idiopathic short stature under active research protocol
• Prader-Willi syndrome or other genetic short-stature syndromes (investigational only)
• Cachexia secondary to chronic illness, under oncology or metabolism specialist oversight

How the Mechanism Differs from Injectable GH

Recombinant human GH (somatropin) replaces a missing hormone directly. MK-677 instructs the child's own pituitary to produce more GH. That distinction matters for dosing: the pituitary's reserve capacity limits the ceiling effect, so escalating the dose beyond a threshold produces diminishing returns on IGF-1 without a proportional increase in benefit. A 2001 pharmacokinetic study in The Journal of Clinical Endocrinology and Metabolism confirmed dose-dependent IGF-1 rises plateau around 25 mg in adults.

Regulatory Status Caregivers Must Understand

The FDA has not approved MK-677 for any indication in any age group as of 2025. The FDA's position on unapproved peptides and growth hormone secretagogues is documented in its guidance on compounded drug products. Any pediatric prescription is either dispensed through a 503A compounding pharmacy under a valid patient-specific order or accessed via an Institutional Review Board-approved clinical trial. Caregivers should confirm which pathway applies to their child before the first dose.

Pharmacology Relevant to Pediatric Caregivers

Understanding what ibutamoren does inside a child's body helps caregivers recognize both expected responses and warning signs.

IGF-1 as the Measurable Signal

MK-677 raises serum insulin-like growth factor 1 (IGF-1), the primary downstream mediator of GH action on bone and muscle. In a 12-week trial by Codner et al. (N=24 children aged 7 to 12 with GHD), oral ibutamoren at 0.1 to 0.8 mg/kg/day normalized IGF-1 standard deviation scores from a mean of -2.4 to -0.6 without serious adverse events. That study, published in The Journal of Clinical Endocrinology and Metabolism, remains one of the most cited pediatric datasets for this compound.

The child's IGF-1 level should be checked at baseline and at 4-week intervals during titration. A target IGF-1 SD score between 0 and +2 for chronological age is a widely used clinical benchmark, consistent with guidance from the Endocrine Society's 2016 GH deficiency clinical practice guidelines.

Ghrelin Receptor Effects Beyond Growth

The ghrelin receptor is expressed in the hypothalamus, stomach, and hippocampus. Activating it with MK-677 produces effects beyond GH release:

• Appetite stimulation (useful in cachectic children; potentially problematic in already well-nourished ones)
• Mild reduction in cortisol secretion after prolonged use, which may blunt the stress response
• Transient increase in fasting glucose due to counter-regulatory GH effects on insulin sensitivity

A meta-analysis of GH secretagogue trials (Nass et al., NEJM 2008) confirmed fasting glucose elevation of 0.3 to 0.5 mmol/L across adult cohorts. Pediatric data is more limited, but the mechanism is identical, so caregivers of children with any personal or family history of type 1 or type 2 diabetes must discuss glucose monitoring frequency with the prescribing physician before starting.

Half-Life and Dosing Timing

MK-677 has a plasma half-life of approximately 4 to 6 hours in adults, though pediatric pharmacokinetic data is sparse. The single daily bedtime dose strategy is designed to coincide with the first natural GH pulse that occurs 60 to 90 minutes after sleep onset, amplifying rather than disrupting circadian GH secretion. Caregivers should give the dose within a consistent 30-minute window each night.

Dosing Framework for Children Under 12

No FDA-approved pediatric dosing table exists for MK-677. The following framework reflects published trial ranges and the clinical experience of endocrinologists who have managed pediatric cases under research or compassionate-use protocols. All doses must be confirmed in writing by the prescribing specialist before administration.

Weight-Based Starting Dose

Published pediatric trials have used 0.1 mg/kg/day as the conservative starting point, with upward titration to 0.8 mg/kg/day based on IGF-1 response and tolerability. For a 25 kg child, that translates to a starting dose of 2.5 mg daily and a maximum evaluated dose of 20 mg daily. Adult studies have used 10 to 25 mg/day as the standard range, and most pediatric specialists keep children under 12 at or below 15 mg regardless of weight.

Titration Schedule

| Week | Dose (example: 25 kg child) | IGF-1 Check | |------|----------------------------|-------------| | 1 to 2 | 2.5 mg at bedtime | No | | 3 to 4 | 5 mg at bedtime | Yes (baseline comparison) | | 5 to 8 | 10 mg at bedtime (if IGF-1 <0 SD) | Week 8 | | 9 to 12 | 15 mg at bedtime (if IGF-1 still <0 SD) | Week 12 |

Dose increases should not occur more frequently than every two weeks. If IGF-1 reaches +2 SD at any point, hold the dose and recheck in 4 weeks rather than continuing to escalate.

Compounded Liquid Formulations

Most children under 12 cannot swallow capsules reliably. A 503A compounding pharmacy can prepare ibutamoren as an oral suspension, typically at 1 mg/mL or 5 mg/mL in a flavored vehicle. Caregivers should:

1. Confirm the concentration in writing before dispensing, because a 10-fold dosing error between 1 mg/mL and 10 mg/mL preparations has been documented in compounded peptide products.
2. Use the oral syringe provided by the pharmacy, not a kitchen teaspoon.
3. Shake the suspension gently (not vigorously) for 10 seconds before drawing each dose.
4. Store the suspension refrigerated at 36 to 46°F and discard after the beyond-use date on the label, which is typically 30 to 60 days.

The FDA's guidance on 503A pharmacy compounding outlines caregiver responsibilities for verifying preparation accuracy.

Step-by-Step Administration Instructions

Consistent technique reduces dose variability and helps caregivers identify unexpected reactions early.

Before the First Dose

• Confirm the child's weight has been recorded within the past 7 days for weight-based dosing accuracy.
• Ensure baseline labs are complete: IGF-1, fasting glucose, HbA1c, and a basic metabolic panel.
• Read the pharmacy's dispensing label aloud with the prescribing clinician on a telehealth visit if possible. Confirm the concentration, the dose in mg, and the volume in mL match the prescription.

Evening Administration Routine

1. Administer the dose 20 to 30 minutes before the child's expected sleep time.
2. Give it on an empty or light-meal stomach. A heavy meal within 60 minutes of dosing may blunt the GH pulse amplitude by elevating somatostatin.
3. Measure the liquid dose with the provided oral syringe, direct it to the inside of the cheek, and have the child swallow followed by 2 to 3 sips of water.
4. Document the time and dose in a simple log (paper or app). Three missed doses in a row should trigger a prescriber call, not an attempt to "catch up."

What Normal Responses Look Like in the First 2 Weeks

Caregivers often worry when expected pharmacological effects appear. Knowing what is normal prevents unnecessary panic:

• Increased appetite within 30 to 60 minutes of the dose is the most common early sign the compound is active.
• Slightly deeper or longer sleep in the first week is frequently reported and consistent with GH-related sleep stage changes.
• Minor water retention (mild facial puffiness in the morning) may appear at higher doses and typically resolves within 2 weeks.

A phase II trial of MK-677 in 65 children with idiopathic short stature (Bright et al., J Clin Endocrinol Metab, 2003) documented increased appetite in 72% of participants and peripheral edema in 18%, both resolving with dose reduction.

Safety Monitoring: What Caregivers Must Track

Pediatric monitoring requirements differ from adult protocols because children's IGF-1 ranges change with age and Tanner stage, and because the consequences of prolonged IGF-1 excess during bone development are not fully characterized.

Glucose Monitoring

Children without a diabetes diagnosis do not need continuous glucose monitoring, but a fasting fingerstick glucose check every 4 weeks during the titration phase is reasonable practice. A single fasting reading above 126 mg/dL warrants same-day prescriber contact. Two consecutive readings above 100 mg/dL (impaired fasting glucose) should prompt a discussion about dose reduction before the next scheduled visit.

The American Diabetes Association's 2024 Standards of Care define fasting glucose thresholds for pediatric prediabetes screening.

Bone Age Monitoring

Because MK-677 raises IGF-1, which accelerates bone maturation, the prescribing endocrinologist will typically order a left-hand bone age X-ray every 6 months. Caregivers do not need to track this independently, but they should ensure these appointments are kept. Bone age advancing faster than chronological age by more than 1 year is a reason to reassess the treatment plan.

Signs Requiring Immediate Prescriber Contact

Stop the dose and call the prescribing physician the same day if the child develops:

• Fasting glucose above 126 mg/dL on two readings taken on separate days
• Noticeable limb or facial swelling that does not resolve within 48 hours
• New headaches occurring daily or upon waking
• Any behavioral change, significant mood disturbance, or sleep-related movement disorder
• Signs of adrenal insufficiency: unusual fatigue, low blood pressure, dizziness on standing

The Endocrine Society's 2016 clinical practice guideline on growth hormone deficiency specifies similar monitoring parameters for all GH axis interventions in children.

Drug Interactions and Co-Administration Considerations

MK-677 is metabolized primarily by CYP3A4. Several medications commonly used in children under 12 may affect its plasma levels or compound its adverse effects.

CYP3A4 Interactions

Azole antifungals (fluconazole, itraconazole) inhibit CYP3A4 and may raise MK-677 plasma concentrations unpredictably. If a child on ibutamoren requires a 7-day or longer antifungal course, the prescribing endocrinologist should be notified before the antifungal is started. Similarly, rifampin (used in some tuberculosis prophylaxis regimens) is a strong CYP3A4 inducer and could reduce ibutamoren efficacy significantly.

Insulin and Oral Hypoglycemics

Children with type 1 diabetes who are being considered for ibutamoren require extra caution. GH elevation raises insulin requirements, and the counter-regulatory effect on glucose could destabilize glycemic control. A 2019 review in Diabetes Care highlighted that GH secretagogues can increase basal insulin requirements by 15 to 30% in type 1 diabetes patients.

Corticosteroids

Prolonged corticosteroid use (prednisolone, dexamethasone) blunts GH axis responsiveness and may reduce the efficacy of MK-677. Caregivers managing children with inflammatory conditions requiring regular steroids should discuss this interaction explicitly with both the endocrinologist and the treating specialist for the underlying condition.

Practical Storage and Handling

Ibutamoren in capsule form is stable at room temperature between 59 to 77°F when kept away from moisture and direct light. Compounded suspensions require refrigeration and are temperature-sensitive: do not freeze them, as freezing disrupts the suspension matrix and leads to uneven dosing.

Travel considerations matter for families. A 30-day supply of capsules fits easily in a carry-on. Suspensions should be transported in an insulated cooler for trips exceeding 4 hours. FDA regulations on transporting compounded preparations across state lines apply; caregivers should carry a copy of the prescription.

If a dose is missed, give it the following evening at the usual time. Do not double the dose.

Communicating With the Medical Team

Caregivers often feel uncertain about when a concern warrants a call versus waiting for a scheduled visit. The following framework helps triage:

Contact the same day (non-emergency):

• Any fasting glucose above 100 mg/dL on two separate days
• Persistent appetite loss (paradoxical, given MK-677 typically increases appetite, but can signal illness)
• New prescription from another provider for a CYP3A4-interacting drug

Contact immediately (treat as urgent):

• Signs of anaphylaxis (hives, throat tightening, wheezing within 30 minutes of a dose)
• Fasting glucose above 126 mg/dL confirmed on a repeat same-day reading
• Suspected adrenal crisis (extreme fatigue, vomiting, low blood pressure)

Routine scheduled visit (do not escalate):

• Increased appetite
• Mild morning facial puffiness resolving by midday
• Child sleeping slightly longer than usual

The treating endocrinologist should receive a copy of the caregiver's dose log at every visit. Most telehealth platforms used by hormone-specialist practices accept a PDF or photo upload before the appointment.

The Evidence Base: What We Know and What We Do Not

Caregivers deserve an honest accounting of the data supporting pediatric ibutamoren use.

What the Trials Show

The Codner et al. Trial (N=24) and the Bright et al. Trial (N=65) together provide the strongest published pediatric evidence. Both showed statistically significant IGF-1 normalization and growth velocity improvements over 12 to 24 weeks. The Bright trial reported a mean increase in height velocity of 2.1 cm/year above baseline in the 0.8 mg/kg/day group, P<0.001.

Long-term data beyond 24 months in children is absent from peer-reviewed literature. Adult long-term studies extend to 24 months. The Murphy et al. 24-month trial (N=65 older adults, NEJM 1998) established that sustained IGF-1 elevation is achievable without tachyphylaxis.

What Remains Unknown

No randomized controlled trial has evaluated ibutamoren's effect on final adult height in children under 12. No study has assessed neurocognitive outcomes, pubertal timing, or bone quality beyond 2 years. Caregivers must weigh the available short-term evidence against these genuine knowledge gaps in consultation with the prescribing specialist.

The Cochrane Collaboration's review of GH secretagogues (2021) noted insufficient long-term pediatric data to support routine use outside of controlled research settings.

When MK-677 Should Not Be Used in a Child Under 12

Absolute contraindications based on available data and pharmacological reasoning include:

• Active malignancy or personal history of malignancy (GH and IGF-1 are mitogenic)
• Closed epiphyses confirmed on bone age imaging
• Known hypersensitivity to ibutamoren or any component of the compounded preparation
• Poorly controlled diabetes mellitus (HbA1c above 8%)
• Prader-Willi syndrome with significant obesity and sleep apnea (GH secretagogues may worsen sleep-disordered breathing)

Relative contraindications requiring specialist discussion include a family history of multiple endocrine neoplasia, any condition requiring ongoing high-dose corticosteroids, and active inflammatory bowel disease with growth failure where underlying disease management should be optimized before adding a GH secretagogue.

The Endocrine Society's position statement on growth hormone and IGF-1 excess emphasizes that mitogenic risk is a primary contraindication consideration for all agents that chronically raise IGF-1.